ArticlePLoS pathogens2012
CD200 receptor controls sex-specific TLR7 responses to viral infection.
Article in PLoS pathogens, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 2 syntheses or guidelines pooled it, 92 citations in OpenAlex.
- COVID-19 pandemic: insights into molecular mechanisms leading to sex-based differences in patient outcomes.Expert reviews in molecular medicine · 2021Pooled it
- The Role of Host Genetic Factors in Coronavirus Susceptibility: Review of Animal and Systematic Review of Human Literature.American journal of human genetics · 2020Pooled it
- Sex differences among inpatients with AECOPD in a tertiary hospital during the COVID-19 pandemic.BMC pulmonary medicine · 2026Article
- Understanding Sex-biases in Kinetoplastid Infections: Leishmaniasis and Trypanosomiasis.Expert reviews in molecular medicine · 2025Review
- Review
- Characteristics of re-admitted adult patients infected with severe acute respiratory syndrome Coronavirus 2 After initial hospitalization at King Salman Armed Forces Hospital, Tabuk, Saudi Arabia.Saudi medical journal · 2023Article
- CD200R1 promotes interleukin-17 production by group 3 innate lymphoid cells by enhancing signal transducer and activator of transcription 3 activation.Mucosal immunology · 2023Article
- Immune Targeted Therapies for COVID-19 Infection: A Narrative Review.Iranian journal of medical sciences · 2022Review
- An Observational Study on Clinical and Epidemiological Profile of Pediatric Patients with Coronavirus Disease 2019 (COVID-19) Presenting With Comorbidities at RIMS, Ranchi.Journal of family medicine and primary care · 2022Article
- Disparate regulation of IMD signaling drives sex differences in infection pathology inProceedings of the National Academy of Sciences of the United States of America · 2021Article
- The CD200 Regulates Inflammation in Mice Independently of TNF-α Production.International journal of molecular sciences · 2021Article
- An overview of Betacoronaviruses-associated severe respiratory syndromes, focusing on sex-type-specific immune responses.International immunopharmacology · 2021Review
- Neurological Manifestations of COVID-19 Feature T Cell Exhaustion and Dedifferentiated Monocytes in Cerebrospinal Fluid.Immunity · 2021Article
- Sex Differences in Immunity to Viral Infections.Frontiers in immunology · 2021Review
- COVID-Pain: Acute and Late-Onset Painful Clinical Manifestations in COVID-19 - Molecular Mechanisms and Research Perspectives.Journal of pain research · 2021Review
- Sexual Dimorphism and Gender in Infectious Diseases.Frontiers in immunology · 2021Review
- Novel coronavirus disease (COVID-19): origin, transmission through the environment, health effects, and mitigation strategies-a review.Environmental sustainability (Singapore) · 2021Review
- Gene-Specific Sex Effects on Susceptibility to Infectious Diseases.Frontiers in immunology · 2021Review
- Identification of a novel conserved signaling motif in CD200 receptor required for its inhibitory function.PloS one · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunological checkpoints, such as the inhibitory CD200 receptor (CD200R), play a dual role in balancing the immune system during microbial infection. On the one hand these inhibitory signals prevent excessive immune mediated pathology but on the other hand they may impair clearance of the pathogen. We studied the influence of the inhibitory CD200-CD200R axis on clearance and pathology in two different virus infection models. We find that lack of CD200R signaling strongly enhances type I interferon (IFN) production and viral clearance and improves the outcome of mouse hepatitis corona virus (MHV) infection, particularly in female mice. MHV clearance is known to be dependent on Toll like receptor 7 (TLR7)-mediated type I IFN production and sex differences in TLR7 responses previously have been reported for humans. We therefore hypothesize that CD200R ligation suppresses TLR7 responses and that release of this inhibition enlarges sex differences in TLR7 signaling. This hypothesis is supported by our findings that in vivo administration of synthetic TLR7 ligand leads to enhanced type I IFN production, particularly in female Cd200(-/-) mice and that CD200R ligation inhibits TLR7 signaling in vitro. In influenza A virus infection we show that viral clearance is determined by sex but not by CD200R signaling. However, absence of CD200R in influenza A virus infection results in enhanced lung neutrophil influx and pathology in females. Thus, CD200-CD200R and sex are host factors that together determine the outcome of viral infection. Our data predict a sex bias in both beneficial and pathological immune responses to virus infection upon therapeutic targeting of CD200-CD200R.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.